JP2007045829A5 - - Google Patents

Download PDF

Info

Publication number
JP2007045829A5
JP2007045829A5 JP2006229517A JP2006229517A JP2007045829A5 JP 2007045829 A5 JP2007045829 A5 JP 2007045829A5 JP 2006229517 A JP2006229517 A JP 2006229517A JP 2006229517 A JP2006229517 A JP 2006229517A JP 2007045829 A5 JP2007045829 A5 JP 2007045829A5
Authority
JP
Japan
Prior art keywords
igfbp
amino acid
binding agent
specific binding
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006229517A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007045829A (ja
JP4467549B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2007045829A publication Critical patent/JP2007045829A/ja
Publication of JP2007045829A5 publication Critical patent/JP2007045829A5/ja
Application granted granted Critical
Publication of JP4467549B2 publication Critical patent/JP4467549B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2006229517A 1999-01-06 2006-08-25 インシュリン様成長因子（ｉｇｆ）ｉ変異体 Expired - Lifetime JP4467549B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11501099P 1999-01-06 1999-01-06

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2005038688A Division JP2005139203A (ja) 1999-01-06 2005-02-16 インシュリン様成長因子（ｉｇｆ）ｉ変異体

Publications (3)

Publication Number Publication Date
JP2007045829A JP2007045829A (ja) 2007-02-22
JP2007045829A5 true JP2007045829A5 (enExample) 2007-04-05
JP4467549B2 JP4467549B2 (ja) 2010-05-26

Family

ID=22358799

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000592320A Withdrawn JP2002535967A (ja) 1999-01-06 2000-01-05 インシュリン様成長因子（ｉｇｆ）ｉ変異体
JP2005038688A Withdrawn JP2005139203A (ja) 1999-01-06 2005-02-16 インシュリン様成長因子（ｉｇｆ）ｉ変異体
JP2006229517A Expired - Lifetime JP4467549B2 (ja) 1999-01-06 2006-08-25 インシュリン様成長因子（ｉｇｆ）ｉ変異体

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2000592320A Withdrawn JP2002535967A (ja) 1999-01-06 2000-01-05 インシュリン様成長因子（ｉｇｆ）ｉ変異体
JP2005038688A Withdrawn JP2005139203A (ja) 1999-01-06 2005-02-16 インシュリン様成長因子（ｉｇｆ）ｉ変異体

Country Status (12)

Country Link
US (6) US6506874B1 (enExample)
EP (1) EP1141015B1 (enExample)
JP (3) JP2002535967A (enExample)
AU (1) AU762047B2 (enExample)
CA (1) CA2356257C (enExample)
CY (1) CY1109452T1 (enExample)
DE (1) DE60042550D1 (enExample)
DK (1) DK1141015T3 (enExample)
ES (1) ES2329220T3 (enExample)
IL (3) IL143834A0 (enExample)
PT (1) PT1141015E (enExample)
WO (1) WO2000040612A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1141014E (pt) * 1999-01-06 2005-04-29 Genentech Inc Variante mutante do factor de crescimento semelhante a insulina (igf-i)
AUPQ585500A0 (en) * 2000-02-25 2000-03-16 Gropep Pty Ltd Treatment for peripheral sensory neuropathy
ES2301547T3 (es) 2000-05-16 2008-07-01 Genentech, Inc. Tratamiento de trastornos del cartilago.
AUPR030900A0 (en) 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
ES2207387B1 (es) * 2002-02-28 2005-07-16 Consejo Sup. Investig. Cientificas Composicion quimica de igf-i para el tratamiento y prevencion de enfermedades neurodegenerativas.
NZ539218A (en) * 2002-09-18 2008-03-28 Univ Montreal Ct Hospitalier Chum Synthetic GHRH analogues of 29 amino acids or more
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ATE536186T1 (de) 2003-09-12 2011-12-15 Tercica Inc Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
WO2005033134A2 (en) * 2003-09-30 2005-04-14 Regeneron Pharmaceuticals, Inc. Secreted protein therapeutics and uses thereof
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
GB0426154D0 (en) * 2004-11-29 2004-12-29 European Molecular Biology Lab Embl IGF-1 novel peptides
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
EP2311880A3 (en) 2005-01-05 2011-07-27 Biogen Idec MA Inc. Cripto binding molecules
EP1841443A4 (en) * 2005-01-11 2012-05-02 Heart Failure Technologies Inc METHOD AND SYSTEM FOR TREATING HEART ERRORS
TWI406870B (zh) * 2005-02-21 2013-09-01 Chugai Pharmaceutical Co Ltd A method of making a protein using hamster IGF-1
FR2892174B1 (fr) 2005-10-14 2007-12-28 Vallourec Mannesmann Oil Gas F Element filete tubulaire muni d'un revetement protecteur sec
EP2059530B1 (en) * 2006-08-31 2012-08-29 F.Hoffmann-La Roche Ag Method for the production of insulin-like growth factor-i
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
RU2010144014A (ru) * 2008-04-03 2012-05-27 Ф. Хоффманн-Ля Рош Аг (Ch) Применение пегилированных вариантов ифр-i для лечения нейромышечных расстройств
BRPI0911266A2 (pt) * 2008-04-03 2015-09-29 Hoffmann La Roche ensaio de fator de crescimento similar à insulina peguilado
WO2010094906A1 (en) * 2009-07-16 2010-08-26 Arecor Limited The stabilisation of proteins
EP2341940A1 (en) * 2008-07-16 2011-07-13 Arecor Limited The stabilisation of proteins
EP2328607A1 (en) * 2008-07-16 2011-06-08 Arecor Limited Stable formulation of a therapeutic protein
BR112012001363A2 (pt) 2009-07-22 2016-11-08 Ipsen Pharma Sas análogo de igf-1, composição farmacêutica,e, método para tratar condições ou doenças mediadas pela ligação do receptor de igf-1
BR112012005485A2 (pt) * 2009-09-10 2016-04-19 Lonza Biologics Plc método e sistema para a purificação de polipeptídeo
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
JP6200806B2 (ja) 2010-05-21 2017-09-20 メリマック ファーマシューティカルズ インコーポレーティッド 二重特異的融合タンパク質
ES2739503T3 (es) 2010-07-09 2020-01-31 Bioverativ Therapeutics Inc Moléculas de cadena simple procesables y polipéptidos producidos usándolas
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
LT2802606T (lt) 2012-01-10 2018-10-10 Biogen Ma Inc. Terapinių molekulių transporto per kraujo-smegenų barjerą padidinimas
KR102182523B1 (ko) * 2012-12-18 2020-11-25 노파르티스 아게 안정화된 인슐린-유사 성장 인자 폴리펩티드
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
US11761951B2 (en) 2015-02-04 2023-09-19 Bristol-Myers Squibb Company Methods of selecting therapeutic molecules
UY36550A (es) 2015-02-04 2016-08-31 Roche Innovation Ct Copenhagen As Oligómeros antisentido de tau y sus usos
CN115960249A (zh) 2015-10-02 2023-04-14 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
EP3453722A1 (en) * 2017-09-06 2019-03-13 Julius-Maximilians-Universität Würzburg Pharmaceuticals and devices for the covalent immobilization to the extracellular matrix by transglutaminase

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
JPH0720993B2 (ja) 1985-08-22 1995-03-08 グロペップ プロプライエタリー リミテッド 生長因子
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
AU627423B2 (en) 1987-04-06 1992-08-27 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them
ES2007309T3 (es) 1987-04-23 1994-11-01 Monsanto Co Secrecion del factor de crecimiento insulinoide 1 en e.coli.
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
WO1989005822A1 (en) * 1987-12-24 1989-06-29 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
ATE86496T1 (de) * 1988-02-05 1993-03-15 Ciba Geigy Ag Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
AU1955388A (en) 1988-04-12 1989-11-03 Synergen, Inc. Method for potentiating and inhibiting insulin-like growth factor activity
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
EP0597033B1 (en) 1991-08-01 1997-04-09 Genentech, Inc. Igf-1 to improve the neural condition
NZ255461A (en) 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
US5342763A (en) 1992-11-23 1994-08-30 Genentech, Inc. Method for producing polypeptide via bacterial fermentation
EP0600372B1 (de) * 1992-12-02 1997-02-05 Hoechst Aktiengesellschaft Verfahren zur Gewinnung von Proinsulin mit korrekt verbundenen Cystinbrücken
US5597700A (en) 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
SE9402331D0 (sv) * 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
JPH11508608A (ja) 1996-04-17 1999-07-27 ニューロクライン バイオサイエンシーズ，インコーポレイテッド インスリン様成長因子結合タンパク質のリガンドインヒビターおよびそれらの使用方法
CA2265972A1 (en) * 1996-09-16 1998-03-26 Philip D. Acott Use of igf-i for the treatment of polycystic kidney disease and related indications
EP0965596A1 (en) 1996-12-27 1999-12-22 Daiichi Pharmaceutical Co., Ltd. Method for elevating the concentration of free insulin-like growth factor
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
DE19757250A1 (de) 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
WO2000023469A2 (en) 1998-10-16 2000-04-27 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
AU5144400A (en) 1999-05-19 2000-12-05 Xencor, Inc. Novel proteins with insulin-like activity useful in the treatment of diabetes

Similar Documents

Publication Publication Date Title
JP2007045829A5 (enExample)
DK2390265T3 (da) Insulinotropisk peptidderivat med modificeret N-terminal aminosyre
JP2010534684A5 (enExample)
SMT201500015B (it) Composizione farmaceutica comprendente (1S)-1,5-anidro-1-[5-(4-etossibenzil)-2- metossi-4-metilfenil]-1-tio-d-glucitolo e un secretagogo dell'insulina
LTPA2017029I1 (lt) Rekombinantinis FSH, įskaitant alfa 2,3- ir alfa 2,6-sialilinimą
PE20090711A1 (es) Region constante de anticuerpo mutante
IL204607A0 (en) Antibodies against osteoclast - related protein siglec - 15, compositions comprising the same and uses thereof
DK1983849T3 (da) Fødevaresammensætning omfattende aminosyrer
DK2035447T3 (da) Polypeptid
IL210589A0 (en) The tuberculosis rv2386c protein, compositions and uses thereof
BRPI0819092A2 (pt) Evolução direcionada usando proteínas que compreendem aminoácidos não naturais.
WO2007060117A3 (de) Chimäre keratinbindende effektorproteine
IL184284A (en) Modified beta thymosin peptides
IL220284A0 (en) Insulin analogues with chlorinated amino acids, compositions comprising the same and uses thereof
PL2004160T3 (pl) Doustna kompozycja o przeciwstarzeniowym działaniu na skórę
FR2900332B1 (fr) Composition dentaire en deux parties.
DE602006018856D1 (de) Neue nutrazeutika-zusammensetzungen
JP2007510403A5 (enExample)
GB0503434D0 (en) Amyloid-binding peptides, analogues and uses thereof
DK1838341T3 (da) Vaccinesammensætning omfattende et fibronectin bindende protein eller et fibronectinbindende peptid
JP2006508095A5 (enExample)
CL2007002769A1 (es) Compuestos derivados de sulfonamida; procedimiento de obtencion; composicion farmaceutica; y uso en el tratamiento de la diabetes.
EP1977800A4 (en) CARD TOY
ATE546152T1 (de) Bakteriocin-vermittler-peptide
FR2881348B1 (fr) Composition cosmetique nettoyante sous forme solide